<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04583384</url>
  </required_header>
  <id_info>
    <org_study_id>APHP200281</org_study_id>
    <secondary_id>2020-A00397-32</secondary_id>
    <nct_id>NCT04583384</nct_id>
  </id_info>
  <brief_title>In Vivo Succinate Detection After External Beam Radiation Therapy in SDHx- Paragangliomas</brief_title>
  <acronym>RADIOSUCCES</acronym>
  <official_title>Evolution of Succinate Accumulation Detected in Vivo by Spectroscopic Magnetic Resonance Imaging (1H-SRM) After External Beam Radiation Therapy in SDHx-mutated Patients With Cervical Paragangliomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Society for Endocrinology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Qualitative and quantitative biomarker of response to radiotherapy is needed in&#xD;
      paragangliomas. We aim at assessing the added value of 1H-SRM for the evaluation of early&#xD;
      response to EBR therapy in patients with cervical SDHx PGL.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Paragangliomas (PGL) are rare neuroendocrine tumors inherited in 40% of cases. SDHx genes&#xD;
      (SDHA, SDHB, SDHC, SDHD), encoding the 4 subunits of the mitochondrial enzyme succinate&#xD;
      dehydrogenase (SDH), are the most frequently involved.&#xD;
&#xD;
      Accumulation of succinate, the substrate for SDH, is a very specific biomarker for these&#xD;
      mutations. Recently, we have demonstrated the feasability of detecting and quantifying&#xD;
      succinate in tumors in vivo, by magnetic resonance spectroscopy (1H-SRM).&#xD;
&#xD;
      Patients carrying these mutations frequently develop cervical PGL for which the treatment of&#xD;
      choice is external beam radiation therapy (EBR).&#xD;
&#xD;
      The objective of this project is to determine the feasibility of using 1H-SRM for the&#xD;
      evaluation of early response to EBR therapy in patients with cervical SDHx PGL.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2020</start_date>
  <completion_date type="Anticipated">June 2025</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disappearance of succinate accumulation at M12</measure>
    <time_frame>12 months</time_frame>
    <description>Absence of succinate accumulation detected in vivo by 1H-SRM, in cervical PGLs with SDHx mutations, at 12 months after EBR, reviewed by 2 independant experts blinded to all other clinical and genetics data.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disapperance of succinate accumulation at M3</measure>
    <time_frame>3 months</time_frame>
    <description>Absence of succinate accumulation detected in vivo by 1H-SRM, in cervical PGLs with SDHx mutations, at 3 months after EBR, reviewed by 2 independant experts blinded to all other clinical and genetics data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Performance of cervical MRI at M3 and M12 after EBR</measure>
    <time_frame>12 months</time_frame>
    <description>Reference diagnostic for response assessed by MRI at 3 months and 12 months after EBR: 1/ Complete response : tumour disappearance ; 2/ Partial response : decrease by at least 30% of tumour volume and no clinical symptomatology worsening ; 3/ stable : stability of tumour size and no clinical symptomatology worsening; 4/ Progression : increase by at least 20% of tumour volume and/or clinical symptomatological worsening</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Performance of PET/CT at M12 after EBR</measure>
    <time_frame>12 months</time_frame>
    <description>PERCIST criteria (PET response criteria in solid tumors) assessed by PET/CT at 3 months and 12 months after EBR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metastatic evolution or death at M12</measure>
    <time_frame>12 months</time_frame>
    <description>Occurence of an event related to the disease during 12 months follow-up (metastatic evolution of the disease or death). Metastases diagnostic is assessed remotely by presence in chromaffin tissue (http://www.sfendocrino.org/article/599/recommandations)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Paraganglioma of Head and Neck</condition>
  <arm_group>
    <arm_group_label>Assigned Intervention</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Addition to the cervical angio-MRI, of a sequence of 1H-SRM 3T (SUCCESS) centered on the lesion studied, performed according to the following parameters: PRESS asymmetric monovoxel &quot;PROBE&quot;, TE 144 ms, TR 2500 ms, 768 or 1024 medium.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>1H-Spectroscopy MRI</intervention_name>
    <description>PRESS asymetric monovoxel &quot; PROBE &quot;, TE 144 ms, TR 2500 ms, 768 or 1024 averages</description>
    <arm_group_label>Assigned Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
          -  Patient with cervical PGL with planning of treatment with EBR&#xD;
&#xD;
          -  Patient with an SDHx mutation or unknown genetic status&#xD;
&#xD;
          -  Patient affiliated to a social security scheme&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant woman&#xD;
&#xD;
          -  Contraindication to MRI (implantable device, etc.)&#xD;
&#xD;
          -  Impossibility of lying down without movement for 45 minutes (hyperalgesic patient,&#xD;
             claustrophobia, etc.)&#xD;
&#xD;
          -  PPGL having previously been the subject of local (excluding surgery) or systemic&#xD;
             treatment&#xD;
&#xD;
          -  PPGL &lt;1 cm longest axis&#xD;
&#xD;
          -  Patient under guardianship or curatorship&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laurence AMAR, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Européen Georges-Pompidou</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Charlotte LUSSEY-LEPOUTRE, PhD</last_name>
    <phone>+33142178370</phone>
    <email>charlotte.lussey@inserm.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Malha BERRAH, MSc</last_name>
    <phone>+33156095822</phone>
    <email>malha.berrah@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hôpital Lariboisière</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Philippe HERMAN, Dr</last_name>
      <phone>+33147711111</phone>
      <email>philippe.herman@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Pitié-Salpêtrière</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Charlotte LUSSEY-LEPOUTRE, Dr</last_name>
      <phone>+33142178370</phone>
      <email>charlotte.lussey@inserm.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital européen Georges Pompidou</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Laurence AMAR, PhD</last_name>
      <phone>+33156093771</phone>
      <email>laurence.amar@aphp.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 5, 2020</study_first_submitted>
  <study_first_submitted_qc>October 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 12, 2020</study_first_posted>
  <last_update_submitted>October 5, 2020</last_update_submitted>
  <last_update_submitted_qc>October 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Paraganglioma,SDHx genes, 1H-Spectroscopy MRI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paraganglioma</mesh_term>
    <mesh_term>Carotid Body Tumor</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual participant data (IPD) that underlie results in publication could be shared.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>Two years after the last publication</ipd_time_frame>
    <ipd_access_criteria>Data sharing must be accepted by the sponsor and the PI based on scientific project and scientific involvement of the PI team.&#xD;
Teams wishing obtain IPD must meet the sponsor and IP team to present scientifics (and commercial) purpose, IPD needed, format of data transmission, and timeframe. Technical feasibility and financial support will be discussed before mandatory contractualization</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

